These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Monoclonal antibody therapy for B-cell lymphoma: clinical trials of an anti-CD20 monoclonal antibody for B-cell lymphoma in Japan. Tobinai K. Int J Hematol; 2002 Dec; 76(5):411-9. PubMed ID: 12512835 [Abstract] [Full Text] [Related]
3. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. Plosker GL, Figgitt DP. Drugs; 2003 Dec; 63(8):803-43. PubMed ID: 12662126 [Abstract] [Full Text] [Related]
4. Monoclonal antibodies for the treatment of hematologic malignancies: clinical trials in Japan. Tobinai K. Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S90-6. PubMed ID: 12819934 [Abstract] [Full Text] [Related]
8. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment. Davis TA, Grillo-López AJ, White CA, McLaughlin P, Czuczman MS, Link BK, Maloney DG, Weaver RL, Rosenberg J, Levy R. J Clin Oncol; 2000 Sep; 18(17):3135-43. PubMed ID: 10963642 [Abstract] [Full Text] [Related]
9. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Maloney DG, Grillo-López AJ, White CA, Bodkin D, Schilder RJ, Neidhart JA, Janakiraman N, Foon KA, Liles TM, Dallaire BK, Wey K, Royston I, Davis T, Levy R. Blood; 1997 Sep 15; 90(6):2188-95. PubMed ID: 9310469 [Abstract] [Full Text] [Related]
12. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma]. Huang HQ, Bu Q, Xia ZJ, Lin XB, Wang FH, Li YH, Peng YL, Pan ZH, Wang SS, Lin TY, Jiang WQ, Guan ZZ. Ai Zheng; 2006 Apr 15; 25(4):486-9. PubMed ID: 16613686 [Abstract] [Full Text] [Related]
18. Re-treatment of relapsed indolent B-cell lymphoma with rituximab. Igarashi T, Ohtsu T, Fujii H, Sasaki Y, Morishima Y, Ogura M, Kagami Y, Kinoshita T, Kasai M, Kiyama Y, Kobayashi Y, Tobinai K, IDEC-C2B8 Study Group. Int J Hematol; 2001 Feb 20; 73(2):213-21. PubMed ID: 11372734 [Abstract] [Full Text] [Related]
19. European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma. Foran JM, Rohatiner AZ, Cunningham D, Popescu RA, Solal-Celigny P, Ghielmini M, Coiffier B, Johnson PW, Gisselbrecht C, Reyes F, Radford JA, Bessell EM, Souleau B, Benzohra A, Lister TA. J Clin Oncol; 2000 Jan 20; 18(2):317-24. PubMed ID: 10637245 [Abstract] [Full Text] [Related]